Bariatric surgery and hypertension

Surgery for Obesity and Related Diseases

Volumn 5, Issue 5, 2009, Pages 615-620

  Bueter, Marco ^a,b   Ahmed, Ahmed ^c   Ashrafian, Hutan ^a   le Roux, Carel W ^a  

^a HAMMERSMITH HOSPITAL   (United Kingdom)

^b UNIVERSITY OF WÜRZBURG   (Germany)

^c CHARING CROSS HOSPITAL   (United Kingdom)

Author keywords

GLP 1; Glucagon like peptide; Gut hormones; Hypertension; Obesity; Salt

Indexed keywords

ALDOSTERONE; ALDOSTERONE RELEASING FACTOR; GLUCAGON LIKE PEPTIDE 1; GLUCAGON LIKE PEPTIDE 1 [7-36] AMIDE; LEPTIN; PLACEBO; UNCLASSIFIED DRUG;

ANTIHYPERTENSIVE ACTIVITY; BARIATRIC SURGERY; CLINICAL TRIAL; DISEASE MODEL; HEMODYNAMICS; HUMAN; HYPERINSULINEMIA; HYPERTENSION; INSULIN RESISTANCE; METABOLIC SYNDROME X; NONHUMAN; OBESITY; OXIDATIVE STRESS; PATHOPHYSIOLOGY; PRIORITY JOURNAL; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; RISK ASSESSMENT; ROUX Y ANASTOMOSIS; STOMACH BYPASS;

BARIATRIC SURGERY; GASTROINTESTINAL HORMONES; HUMANS; HYPERTENSION; OBESITY, MORBID;

EID: 70249084480     PISSN: 15507289     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.soard.2009.03.218     Document Type: Review

References (71)

1. Visscher T.L., and Seidell J.C. The public health impact of obesity. Annu Rev Public Health 22 (2001) 355-375
2. Allison D.B., and Saunders S.E. Obesity in North America: an overview. Med Clin North Am 84 (2000) 305-332 v
3. Hedley A.A., Ogden C.L., Johnson C.L., et al. Prevalence of overweight and obesity among US children, adolescents, and adults, 1999-2002. JAMA 291 (2004) 2847-2850
4. Hall J.E. The kidney, hypertension, and obesity. Hypertension 41 (2003) 625-633
5. Ashrafian H., le Roux C.W., Darzi A., et al. Effects of bariatric surgery on cardiovascular function. Circulation 118 (2008) 2091-2102
6. le Roux C.W., Aylwin S.J., Batterham R.L., et al. Gut hormone profiles following bariatric surgery favor an anorectic state, facilitate weight loss, and improve metabolic parameters. Ann Surg 243 (2006) 108-114
7. Rubino F., Gagner M., Gentileschi P., et al. The early effect of the Roux-en-Y gastric bypass on hormones involved in body weight regulation and glucose metabolism. Ann Surg 240 (2004) 236-242
8. Kannel W.B., Brand N., Skinner Jr. J.J., et al. The relation of adiposity to blood pressure and development of hypertension: the Framingham study. Ann Intern Med 67 (1967) 48-59
9. Stamler R., Stamler J., Riedlinger W.F., et al. Weight and blood pressure: findings in hypertension screening of 1 million Americans. JAMA 240 (1978) 1607-1610
10. Natali A., Quinones G.A., Santoro D., et al. Relationship between insulin release, antinatriuresis and hypokalaemia after glucose ingestion in normal and hypertensive man. Clin Sci (Lond) 85 (1993) 327-335
11. DeFronzo R.A., Cooke C.R., Andres R., et al. The effect of insulin on renal handling of sodium, potassium, calcium, and phosphate in man. J Clin Invest 55 (1975) 845-855
12. Strazzullo P., Barbato A., Galletti F., et al. Abnormalities of renal sodium handling in the metabolic syndrome. Results of the Olivetti Heart Study. J Hypertens 24 (2006) 1633-1639
13. Fujita T. Aldosterone in salt-sensitive hypertension and metabolic syndrome. J Mol Med 86 (2008) 729-734
14. Rahmouni K., Morgan D.A., Morgan G.M., et al. Hypothalamic PI3K and MAPK differentially mediate regional sympathetic activation to insulin. J Clin Invest 114 (2004) 652-658
15. Rahmouni K., Haynes W.G., Morgan D.A., et al. Role of melanocortin-4 receptors in mediating renal sympathoactivation to leptin and insulin. J Neurosci 23 (2003) 5998-6004
16. Laragh J. Laragh's lessons in pathophysiology and clinical pearls for treating hypertension. Am J Hypertens 14 (2001) 397-404
17. Connell J.M., and Davies E. The new biology of aldosterone. J Endocrinol 186 (2005) 1-20
18. Mitchell R.A., Liao H., Chesney J., et al. Macrophage migration inhibitory factor (MIF) sustains macrophage proinflammatory function by inhibiting p53: regulatory role in the innate immune response. Proc Natl Acad Sci USA 99 (2002) 345-350
19. Bagby S.P. Obesity-initiated metabolic syndrome and the kidney: a recipe for chronic kidney disease?. J Am Soc Nephrol 15 (2004) 2775-2791
20. El-Atat F.A., Stas S.N., McFarlane S.I., et al. The relationship between hyperinsulinemia, hypertension and progressive renal disease. J Am Soc Nephrol 15 (2004) 2816-2827
21. Toh M.L., Aeberli D., Lacey D., et al. Regulation of IL-1 and TNF receptor expression and function by endogenous macrophage migration inhibitory factor. J Immunol 177 (2006) 4818-4825
22. Bochud M., Nussberger J., Bovet P., et al. Plasma aldosterone is independently associated with the metabolic syndrome. Hypertension 48 (2006) 239-245
23. Praga M., and Morales E. Obesity, proteinuria and progression of renal failure. Curr Opin Nephrol Hypertens 15 (2006) 481-486
24. Ehrhart-Bornstein M., Lamounier-Zepter V., Schraven A., et al. Human adipocytes secrete mineralocorticoid-releasing factors. Proc Natl Acad Sci USA 100 (2003) 14211-14216
25. Fujita T. Aldosterone in salt-sensitive hypertension and metabolic syndrome. J Mol Med 86 (2008) 729-734
26. Nagase M., Shibata S., Yoshida S., et al. Podocyte injury underlies the glomerulopathy of Dahl salt-hypertensive rats and is reversed by aldosterone blocker. Hypertension 47 (2006) 1084-1093
27. Sugerman H., Windsor A., Bessos M., et al. Effects of surgically induced weight loss on urinary bladder pressure, sagittal abdominal diameter and obesity co-morbidity. Int J Obes Relat Metab Disord 22 (1998) 230-235
28. Sugerman H., Windsor A., Bessos M., et al. Intra-abdominal pressure, sagittal abdominal diameter and obesity comorbidity. J Intern Med 241 (1997) 71-79
29. Valensi P., Assayag M., Busby M., et al. Microalbuminuria in obese patients with or without hypertension. Int J Obes Relat Metab Disord 20 (1996) 574-579
30. Weisinger J.R., Kempson R.L., Eldridge F.L., et al. The nephrotic syndrome: a complication of massive obesity. Ann Intern Med 81 (1974) 440-447
31. Bloomfield G.L., Blocher C.R., Fakhry I.F., et al. Elevated intra-abdominal pressure increases plasma renin activity and aldosterone levels. J Trauma 42 (1997) 997-1004
32. Mutoh T., Lamm W.J., Embree L.J., et al. Abdominal distension alters regional pleural pressures and chest wall mechanics in pigs in vivo. J Appl Physiol 70 (1991) 2611-2618
33. Ridings P.C., Bloomfield G.L., Blocher C.R., et al. Cardiopulmonary effects of raised intra-abdominal pressure before and after intravascular volume expansion. J Trauma 39 (1995) 1071-1075
34. Doty J.M., Saggi B.H., Sugerman H.J., et al. Effect of increased renal venous pressure on renal function. J Trauma 47 (1999) 1000-1003
35. Bloomfield G.L., Sugerman H.J., Blocher C.R., et al. Chronically increased intra-abdominal pressure produces systemic hypertension in dogs. Int J Obes Relat Metab Disord 24 (2000) 819-824
36. Galletti F., D'Elia L., Barba G., et al. High-circulating leptin levels are associated with greater risk of hypertension in men independently of body mass and insulin resistance: results of an eight-year follow-up study. J Clin Endocrinol Metab 93 (2008) 3922-3926
37. Eikelis N., and Esler M. The neurobiology of human obesity. Exp Physiol 90 (2005) 673-682
38. Rahmouni K., Correia M.L., Haynes W.G., et al. Obesity-associated hypertension: new insights into mechanisms. Hypertension 45 (2005) 9-14
39. Mark A.L., Shaffer R.A., Correia M.L., et al. Contrasting blood pressure effects of obesity in leptin-deficient ob/ob mice and agouti yellow obese mice. J Hypertens 17 (1999) 1949-1953
40. Esler M., Straznicky N., Eikelis N., et al. Mechanisms of sympathetic activation in obesity-related hypertension. Hypertension 48 (2006) 787-796
41. Izawa-Abe M., Ogawa Y., Masuzaki H., et al. Pathophysiological role of leptin in obesity-related hypertension. J Clin Invest 105 (2000) 1243-1252
42. Buchwald H., Schwartz M.Z., and Varco R.L. Surgical treatment of obesity. Adv Surg 7 (1973) 235-255
43. Buchwald H., Husemann B., Leutenegger A.F., et al. Morbid obesity-surgical treatment-when and how?. Langenbecks Arch Chir 368 (1986) 73-79
44. Sjostrom L., Lindroos A.K., Peltonen M., et al. Lifestyle, diabetes, and cardiovascular risk factors 10 years after bariatric surgery. N Engl J Med 351 (2004) 2683-2693
45. Sjostrom L., Narbro K., Sjostrom C.D., et al. Effects of bariatric surgery on mortality in Swedish obese subjects. N Engl J Med 357 (2007) 741-752
46. Buchwald H., Avidor Y., Braunwald E., et al. Bariatric surgery: a systematic review and meta-analysis. JAMA 292 (2004) 1724-1737
47. Garcia de la T.N., Rubio M.A., Bordiu E., et al. Effects of weight loss after bariatric surgery for morbid obesity on vascular endothelial growth factor-A, adipocytokines, and insulin. J Clin Endocrinol Metab 93 (2008) 4276-4281
48. Dall'asta C., Vedani P., Manunta P., et al. Effect of weight loss through laparoscopic gastric banding on blood pressure, plasma renin activity and aldosterone levels in morbid obesity. Nutr Metab Cardiovasc Dis (2008 Aug 18)
49. Ruano M., Silvestre V., Castro R., et al. Morbid obesity, hypertensive disease and the renin-angiotensin-aldosterone axis. Obes Surg 15 (2005) 670-676
50. Smith B.R., Hinojosa M.W., Reavis K.M., et al. Remission of diabetes after laparoscopic gastric bypass. Am Surg 74 (2008) 948-952
51. Ahmed A.R., Rickards G., Coniglio D., et al. Laparoscopic Roux-en-Y gastric bypass and its early effect on blood pressure. Obes Surg (2008 Aug 30)
52. Rubino F. Is type 2 diabetes an operable intestinal disease?. A provocative yet reasonable hypothesis. Diabetes Care 31 Suppl 2 (2008) S290-S296
53. le Roux C.W., Welbourn R., Werling M., et al. Gut hormones as mediators of appetite and weight loss after Roux-en-Y gastric bypass. Ann Surg 246 (2007) 780-785
54. Mason E.E. The mechanisms of surgical treatment of type 2 diabetes. Obes Surg 15 (2005) 459-461
55. Patriti A., Facchiano E., Sanna A., et al. The enteroinsular axis and the recovery from type 2 diabetes after bariatric surgery. Obes Surg 14 (2004) 840-848
56. Pories W.J., and Albrecht R.J. Etiology of type II diabetes mellitus: role of the foregut. World J Surg 25 (2001) 527-531
57. McIntyre N., Holdsworth C.D., and Turner D.S. New interpretation of oral glucose tolerance. Lancet 2 (1964) 20-21
58. Lennane R.J., Carey R.M., Goodwin T.J., et al. A comparison of natriuresis after oral and intravenous sodium loading in sodium-depleted man: evidence for a gastrointestinal or portal monitor of sodium intake. Clin Sci Mol Med 49 (1975) 437-440
59. Singer D.R., Markandu N.D., Buckley M.G., et al. Contrasting endocrine responses to acute oral compared with intravenous sodium loading in normal humans. Am J Physiol 274 (1998) F111-F119
60. Mu J.Y., Hansson G.C., and Lundgren O. The intestinal tract and the pathophysiology of arterial hypertension: an experimental study on Dahl rats. Acta Physiol Scand 155 (1995) 137-146
61. Morgan D.A., DiBona G.F., and Mark A.L. Effects of interstrain renal transplantation on NaCl-induced hypertension in Dahl rats. Hypertension 15 (1990) 436-442
62. Bouhnik J., Richoux J.P., Huang H., et al. Hypertension in Dahl salt-sensitive rats: biochemical and immunohistochemical studies. Clin Sci (Lond) 83 (1992) 13-22
63. Sterzel R.B., Luft F.C., Gao Y., et al. Atrial natriuretic factor in sodium-sensitive and sodium-resistant Dahl rats. J Hypertens 5 (1987) 17-24
64. Michell A.R., Debnam E.S., and Unwin R.J. Regulation of renal function by the gastrointestinal tract: potential role of gut-derived peptides and hormones. Annu Rev Physiol 70 (2008) 379-403
65. Tang-Christensen M., Larsen P.J., Goke R., et al. Central administration of GLP-1-(7-36) amide inhibits food and water intake in rats. Am J Physiol 271 (1996) R848-R856
66. Meeran K., O'Shea D., Edwards C.M., et al. Repeated intracerebroventricular administration of glucagon-like peptide-1-(7-36) amide or exendin-(9-39) alters body weight in the rat. Endocrinology 140 (1999) 244-250
67. Moreno C., Mistry M., and Roman R.J. Renal effects of glucagon-like peptide in rats. Eur J Pharmacol 434 (2002) 163-167
68. Yu M., Moreno C., Hoagland K.M., et al. Antihypertensive effect of glucagon-like peptide 1 in Dahl salt-sensitive rats. J Hypertens 21 (2003) 1125-1135
69. Gutzwiller J.P., Hruz P., Huber A.R., et al. Glucagon-like peptide-1 is involved in sodium and water homeostasis in humans. Digestion 73 (2006) 142-150
70. Gutzwiller J.P., Tschopp S., Bock A., et al. Glucagon-like peptide 1 induces natriuresis in healthy subjects and in insulin-resistant obese men. J Clin Endocrinol Metab 89 (2004) 3055-3061
71. Herrmann C., Goke R., Richter G., et al. Glucagon-like peptide-1 and glucose-dependent insulin-releasing polypeptide plasma levels in response to nutrients. Digestion 56 (1995) 117-126